ReNeuron Group (LSE: RENE)28.5p, Mkt Cap: £16.26m. Reported finals to March 2022 on Monday and has been on the cutting edge of Proprietary Stem Cell technologies having listed in 2005. The business Strategy, blunted by lack of success is fully focused on expanding its Exosome platform. (Exosomes are nano‐sized and serve as mediators for cell‐to‐cell communication). These results reported progress with seven discovery-stage collaborations with global pharma, biotech and academic institutions. The pre-clinical data shows that ReNeuron's exosome drug delivery technology...
